William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, Inc., filed a Form 4 on November 3, 2026, disclosing the acquisition of 13,705 shares of common stock on October 30, 2026, following the achievement of a performance-based vesting condition.

Key Highlights

  • Reporting person: William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, Inc. (NASDAQ:ASMB)
  • Transaction: 13,705 shares of common stock acquired (transaction code A) on October 30, 2026, at a price of $0
  • Source of shares: A performance-based restricted stock unit award originally dated June 16, 2025
  • Vesting trigger: A performance-based vesting condition was achieved on October 30, 2026
  • Vesting schedule: Shares vest in two equal installments on October 30, 2026, and October 30, 2027, subject to continuous service
  • Beneficial ownership following transaction: 74,035 shares of common stock held directly

Assembly Biosciences CSO Delaney Reports Performance RSU Vesting on October 30, 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 3, 2026, William E. Delaney IV, serving as Chief Scientific Officer at Assembly Biosciences, Inc. (NASDAQ:ASMB), reported the acquisition of 13,705 shares of common stock. The filing indicates the transaction date was October 30, 2026, and the shares were acquired at a price of $0, reflecting their origin as a stock award rather than an open-market purchase.

The filing discloses that the 13,705 shares are "issuable under a performance-based restricted stock unit award dated June 16, 2025." According to the explanation of responses, "on October 30, 2026, a performance-based vesting condition was achieved." The award vests in two equal installments, with the first installment on October 30, 2026, and the second on October 30, 2027, in each case "assuming continuous service on each vesting date." The form was signed by John O. Gunderson as Attorney-in-Fact on November 3, 2026.

Following the reported transaction, the filing states that Delaney directly beneficially owns 74,035 shares of Assembly Biosciences common stock. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Assembly Biosciences Chief Scientific Officer William E. Delaney IV disclosed the acquisition of 13,705 shares of common stock on October 30, 2026, at $0 per share, resulting from the achievement of a performance condition under a June 16, 2025 RSU award, bringing his direct beneficial ownership to 74,035 shares.